Skip to menu Skip to content Skip to footer
Dr Mark Effron
Dr

Mark Effron

Email: 

Overview

Availability

Dr Mark Effron is:
Available for supervision

Works

Search Professor Mark Effron’s works on UQ eSpace

170 works between 1978 and 2025

161 - 170 of 170 works

1997

Conference Publication

Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results

Ellis, SG, Serruys, PW, Popma, JJ, Teirstein, PS, Ricci, DR, Gold, HK and Effron, MB (1997). Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. DALLAS: AMER HEART ASSOC.

Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results

1997

Journal Article

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction

Fuster, , Califf, RM, Chesebro, JH, Cohen, M, Comp, PC, Gheorghiade, M, Hall, J, Halperin, J, Khan, S, Kopecky, S, Langer, A, Molk, B, Moss, A, OConnor, CM, OGara, PT, Raskob, E, Sutton, J, Braunwald, E, Bell, WR, Furberg, C, Rapaport, E, DeMets, D, Goldstein, S, Richardson, D, Hillis, D, Bonow, R, Kistler, JP, Mohr, JP, Sherman, D ... Smith, C (1997). Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet, 350 (9075), 389-396.

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction

1997

Journal Article

The effect of digoxin on mortality and morbidity in patients with heart failure

Perry, G, Brown, E, Thornton, R, Shiva, T, Hubbard, J, Reddy, KR, Doherty, JE, Cardello, FP, Fast, A, Radford, MJ, Folger, JS, Bhaskar, G, Zoble, RG, Sridharan, , Sridharan, MR, Loungani, RR, Gheorghiade, M, Hsieh, A, Tommaso, C, Mansuri, M, Guess, MA, Akhtar, S, Wagner, S, Hagan, K, McIntyre, KM, Ruble, P, Moten, M, Riley, A, Pierpont, G ... Singh, BN (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine, 336 (8), 525-533.

The effect of digoxin on mortality and morbidity in patients with heart failure

1996

Journal Article

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina - A randomized multicenter trial

Schulman, SP, GoldschmidtClermont, PJ, Topol, EJ, Califf, RM, Navetta, FI, Willerson, JT, Chandra, NC, Guerci, AD, Ferguson, JJ, Harrington, RA, Lincoff, AM, Yakubov, SJ, Bray, PF, Bahr, RD, Wolfe, CL, Yock, PG, Anderson, HV, Nygaard, TW, Mason, SJ, Effron, MB, Fatterpacker, A, Raskin, S, Smith, J, Brashears, L, Gottdiener, P, duMee, C, Kitt, MM and Gerstenblith, G (1996). Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina - A randomized multicenter trial. Circulation, 94 (9), 2083-2089. doi: 10.1161/01.CIR.94.9.2083

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina - A randomized multicenter trial

1996

Journal Article

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

Abernathy, GT, Abrams, J, Akhtar, S, Albitar, , Amidi, M, Anand, IS, Arnold, JMO, Ashton, T, Aubrey, B, Auger, P, Babb, J, Baigrie, R, Baird, MG, Baitz, T, Barber, NC, Barbour, DJ, Barr, DM, Basu, AK, Baughman, KL, Beckham, , BekheitSaad, S, Berkson, DM, Bertoglio, M, Bessoudo, R, Beaudoin, J, Bhaskar, G, Binder, A, Bloomfield, D, Bodine, K ... Martinez, G (1996). Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials, 17 (1), 77-97.

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

1996

Journal Article

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

Mindlen, F, Nordaby, R, Ruiz, M, Zavala, A, Guzman, L, Martinez, F, Diaz, RR, Mackey, C, Marino, M, Romero, G, Zapata, G, Cuneo, C, Kawamura, T, Coelho, O, Massayochi, O, Braga, J, Labrunie, A, Bodanese, L, Manenti, E, Vitola, D, Nicolau, J, Amodeo, C, Armaganijan, D, Bertolami, M, Caramelli, B, Carvalho, A, Cirenza, C, Fichino, M, Franken, R ... Kennedy, JW (1996). The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology, 12 (2), 127-137.

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

1988

Journal Article

TRANSIENT ATRIAL DYSFUNCTION AFTER CONVERSION OF CHRONIC ATRIAL-FIBRILLATION TO SINUS RHYTHM

SHAPIRO, EP, EFFRON, MB, LIMA, S, OUYANG, P, SIU, CO and BUSH, D (1988). TRANSIENT ATRIAL DYSFUNCTION AFTER CONVERSION OF CHRONIC ATRIAL-FIBRILLATION TO SINUS RHYTHM. American Journal of Cardiology, 62 (17), 1202-1207. doi: 10.1016/0002-9149(88)90260-3

TRANSIENT ATRIAL DYSFUNCTION AFTER CONVERSION OF CHRONIC ATRIAL-FIBRILLATION TO SINUS RHYTHM

1987

Journal Article

CHANGES IN MYOSIN ISOENZYMES, ATPASE ACTIVITY, AND CONTRACTION DURATION IN RAT CARDIAC-MUSCLE WITH AGING CAN BE MODULATED BY THYROXINE

EFFRON, MB, BHATNAGAR, GM, SPURGEON, HA, RUANOARROYO, G and LAKATTA, EG (1987). CHANGES IN MYOSIN ISOENZYMES, ATPASE ACTIVITY, AND CONTRACTION DURATION IN RAT CARDIAC-MUSCLE WITH AGING CAN BE MODULATED BY THYROXINE. Circulation Research, 60 (2), 238-245. doi: 10.1161/01.RES.60.2.238

CHANGES IN MYOSIN ISOENZYMES, ATPASE ACTIVITY, AND CONTRACTION DURATION IN RAT CARDIAC-MUSCLE WITH AGING CAN BE MODULATED BY THYROXINE

1980

Journal Article

MECHANISMS OF BLOOD-FLOW DURING CARDIOPULMONARY RESUSCITATION

RUDIKOFF, MT, MAUGHAN, WL, EFFRON, M, FREUND, P and WEISFELDT, ML (1980). MECHANISMS OF BLOOD-FLOW DURING CARDIOPULMONARY RESUSCITATION. Circulation, 61 (2), 345-352. doi: 10.1161/01.CIR.61.2.345

MECHANISMS OF BLOOD-FLOW DURING CARDIOPULMONARY RESUSCITATION

1978

Journal Article

EFFECT OF TRIS(HYDROXYMETHYL)AMINOMETHANE ON ISCHEMIC MYOCARDIUM

EFFRON, MB, GUARNIERI, T, FREDERIKSEN, JW, GREENE, HL and WEISFELDT, ML (1978). EFFECT OF TRIS(HYDROXYMETHYL)AMINOMETHANE ON ISCHEMIC MYOCARDIUM. American Journal of Physiology, 235 (2), H167-H174. doi: 10.1152/ajpheart.1978.235.2.H167

EFFECT OF TRIS(HYDROXYMETHYL)AMINOMETHANE ON ISCHEMIC MYOCARDIUM

Supervision

Availability

Dr Mark Effron is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Dr Mark Effron's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au